RxDoctor Payments DataLook up a doctor →

Daniel Lee, MD

Interventional Cardiology · Saginaw, MINPI 1861472367

Payments from drug & device makers

$314,833in general payments, 2019–2025

Across 800 payments — averaging $393.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$114K
  • Abbott$66K
  • Johnson & Johnson$61K
  • AstraZeneca$51K
  • Biotronik Inc.$11K
  • Novartis$3K
  • plus $9K from 34 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$167,38588%
  • Travel & lodging$7,0834%
  • Food & beverage$14,5228%
  • Education$6810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$314,833 in reported general payments places this provider in the 85th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$170,482
Medicare patients
707
Services billed
1,794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban453$583,406
AdempasRiociguat32$444,874
EliquisApixaban263$329,769
Repatha SureclickEvolocumab305$327,729
OpsumitMacitentan12$151,394
EntrestoSacubitril/Valsartan87$117,744
FarxigaDapagliflozin Propanediol68$100,502
JardianceEmpagliflozin53$85,524
Repatha SyringeEvolocumab40$38,584
MultaqDronedarone Hcl17$30,958
BrilintaTicagrelor32$23,813
Praluent PenAlirocumab22$16,123
Rosuvastatin Calcium663$14,898
Atorvastatin Calcium707$13,004
Ezetimibe184$4,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$61,127$583,406453 claims
BayerAdempas$476$444,87432 claims
PfizerEliquis$538$329,769263 claims
Actelion Pharmaceuticals US, Inc.Opsumit$207$151,39412 claims
AstraZenecaFarxiga, Brilinta$51,263$124,315100 claims
NovartisEntresto$2,949$117,74487 claims
Boehringer IngelheimJardiance$590$85,52453 claims
Sanofi-aventis U.S. LLCMultaq$68$30,95817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →